LTX-315 (Ruxotemitide)
Also known as: Ruxotemitide
An oncolytic nine-amino-acid peptide injected into tumors, in clinical trials for melanoma and other solid tumors. Investigational; not approved.
Last updated
Mechanism of Action
LTX-315 is a cationic, amphipathic nine-residue peptide derived from bovine lactoferricin. Injected directly into a tumor, it disrupts cancer cell plasma and mitochondrial membranes, causing rapid immunogenic cell death with release of danger signals such as ATP, HMGB1 and calreticulin along with tumor antigens. This is thought to activate dendritic cells and increase tumor-infiltrating T cells, turning poorly immunogenic tumors into ones that respond better to checkpoint inhibitors.
- Half-life
- Not well established
- Administration Routes
- Intratumoral
- Research Status
- Clinical
Reported Benefits
- Phase 1 dose-ranging trial in solid tumors showed increased tumor T-cell infiltration
- Studied with pembrolizumab in PD-1-refractory advanced melanoma (phase 2)
- Studied with adoptive T-cell therapy in metastatic soft tissue sarcoma
- Being evaluated before surgery (neoadjuvant) in resectable melanoma
Potential Side Effects
- Injection-site pain and reactions
- Hypotension and flushing
- Hypersensitivity or anaphylactoid reactions
- Fatigue
Common Dosing
No approved dose. Trial regimens have injected the peptide directly into accessible tumors over repeated sessions, given by oncology teams, often combined with a checkpoint inhibitor. Use is limited to clinical trials.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Investigational: not established
No documented stacking partners for LTX-315 (Ruxotemitide) yet.
- View
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
2021
- View
LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma
2024